Izvorni znanstveni članak
A Single-Centre Experience with Octreotide in the Treatment of Different Hypersecretory Syndromes in Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors
Maja Cigrovski Berković
Velimir Altabas
Davorka Herman
Davor Hrabar
Vesna Goldon
Branka Vizner
Vanja Zjačić-Rotkvić
Sažetak
The aim of this research was to assess the clinical and biochemical efficacy of the octreotide in the treatment of patients
with various functional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study included 14 patients
treated with octreotide for 6 months. They were diagnosed with VIPoma, glucagonoma, gastrinoma, medullary
thyroid carcinoma (solitary and as a part of MEN-II syndrome), pancreatic carcinoids (solitary and as a part of multiple
endocrine neoplasia type-1 syndrome-MEN-1 syndrome) and midgut carcinoids. The patients presented with Verner-
-Morrison, glucagonoma, Zollinger Ellison and carcinoid syndrome respectively. All had a metastatic disease at the time
of diagnosis and a positive octreoscan finding. Initially elevated chromogranin A (CgA) levels were detected in 11 (78.6%)
and elevated 5-hydroxyindolacetic acid (5-HIAA) levels in 8 (57.1%) patients. Symptomatic efficacy assessments were
made by diarrhea reductions during treatment course, and laboratory efficacy was assessed through changes in 5-HIAA
and CgA levels. Assessments were made initially and following 6 months of therapy. Median urinary 5-HIAA and the
number of stools decreased significantly (p=0.016 and p=0.009 respectively, p<0.05) while CgA levels had the decreasing
tendency but not statistically significant (p=0.14). There was a positive correlation between the 5-HIAA reduction
and the decrease in stool number at baseline and during treatment course (p<0.05). No correlation was observed between
5-HIAA and CgA levels and also there was no correlation between CgA reduction and symptomatic improvement. The results
prove octreotide to be effective in reducing symptoms and biochemical markers associated with hypersecretory syndromes
of GEP-NETs.
Ključne riječi
gastroenteropancreatic neuroendocrine tumors; carcinoid syndrome; hypersecretory syndromes; octreotide; 5-hydroxyindolacetic acid; chromogranin A
Hrčak ID:
27373
URI
Datum izdavanja:
10.4.2007.
Posjeta: 1.211 *